The Amsterdam-based European Medicines Agency has cleared the coronavirus vaccine developed by Leiden based pharmaceuticals company Janssen for general use on adults.
The Netherlands has ordered 11.3 million doses of the single-dose Johnson & Johnson vaccine, of which some three million doses are slated for delivery in the second quarter of the year.
The vaccine is the fourth to be approved by the EMA, following backing for the Pfizer/BioNTech, Moderna and AstraZeneca versions. Unlike these vaccines, the Janssen vaccine can be kept in an ordinary fridge.
Two weeks after the jab, the vaccine has an efficacy of 67%, the Dutch medicine body CBG said. It prevents 85% of serious illnesses and a 100% record on preventing death.
The side effects in the study were usually mild or moderate and cleared within a couple of days after vaccination, the EMA said. The most common ones were pain at the injection site, headache, tiredness, muscle pain and nausea.
The vaccine is already being used in the US, where it was approved earlier.
The approval for fast track release comes on the same day as Denmark said it would stop using the AstraZeneca vaccine because of a potential link with thrombosis.
The EMA has already said it considers a link to be unlikely but is due to make a second statement later on Thursday afternoon.
Thank you for donating to DutchNews.nl
The DutchNews.nl team would like to thank all the generous readers who have made a donation in recent weeks. Your financial support has helped us to expand our coverage of the coronavirus crisis into the evenings and weekends and make sure you are kept up to date with the latest developments.
DutchNews.nl has been free for 14 years, but without the financial backing of our readers, we would not be able to provide you with fair and accurate news and features about all things Dutch. Your contributions make this possible.